Compare IVT & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVT | ANIP |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | IVT | ANIP |
|---|---|---|
| Price | $28.62 | $76.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $32.20 | ★ $105.83 |
| AVG Volume (30 Days) | ★ 555.4K | 462.3K |
| Earning Date | 02-10-2026 | 02-27-2026 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | ★ 1421.59 | N/A |
| EPS | 1.51 | ★ 1.67 |
| Revenue | $293,020,000.00 | ★ $826,880,000.00 |
| Revenue This Year | $9.77 | $44.06 |
| Revenue Next Year | $7.05 | $9.06 |
| P/E Ratio | ★ $19.00 | $45.54 |
| Revenue Growth | 9.60 | ★ 48.87 |
| 52 Week Low | $25.21 | $52.74 |
| 52 Week High | $31.04 | $99.50 |
| Indicator | IVT | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 34.94 |
| Support Level | $28.42 | $76.69 |
| Resistance Level | $29.50 | $80.29 |
| Average True Range (ATR) | 0.48 | 2.79 |
| MACD | 0.02 | -0.14 |
| Stochastic Oscillator | 52.57 | 7.87 |
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.